Rapid Immunodetection in Clinical and Pharmaceutical Applications
: 30 Jun 2021
Sector: Clinical, Pharmaceutical
Faster immunodetection has always been a target among life science researchers. Nowadays lateral flow test is the most popular format of Point of Care Test (POCT) which typically takes 15 minutes to complete and qualitatively detects a soluble antigen. In this webinar, we introduce a new immunodetection technology, direct immunohistochemistry (IHC) which also takes 10-15 minutes to complete but qualitatively detects solid phase antigens in tissue or cells. Direct IHC opens multiple new applications in pathology diagnostics and pharmaceutical companion diagnostics. Meanwhile, we would like to introduce a novel inhibition lateral flow test detecting SARS-CoV-2 neutralizing antibodies.
Jeffrey Wang, Ph.D. CEO of Novodiax, Inc.
Graduated from Capital Medical College in Beijing, obtained MSc from Union Medical College, Beijing and PhD from Max Planck Institute for Molecular Genetics, Berlin and trained as a Post-Doc in UCSF.
Worked as a research scientist and R&D Manager in Biogenex developing tissue-based diagnostic products, as a Principal Scientist in Chiron (Currently part of Novartis) developing antibody therapeutics, as R&D Director in Multispan focusing on GPCR drug screening services, as CSO cofounded Digitab where the focus was development of a new diagnostic technology platform. Since 2009, cofounded Novodiax, Inc and serving as its CEO.